Jami'ar Athens Strati A et al. ya ruwaito cewa ko PD-L1 ya wuce gona da iri a cikin ƙwayoyin cuta masu yaduwa (CTC) na iya samar da ƙarin yuwuwar kuma mahimman bayanai masu fa'ida ga marasa lafiya da ciwon daji na squamous cell carcinoma. Bayan jiyya, marasa lafiya tare da tabbataccen PD-L1 a cikin CTC suna karɓar adjuvant PD1 maganin kashewa sun cancanci ƙarin kimantawa. (Ann Oncol. 2017; 28: 1923-1933.)
Based on the tumor’s biological markers, it can be determined whether PD 1 checkpoint inhibitors may ultimately benefit some patients with kai da wuyansa squamous cell carcinoma. The molecular characteristics of circulating tumo cells are critical for studying targeted therapy of tumors, and the biomarkers that predict PD 1 checkpoint inhibitors are still unclear. This prospective study included a group of patients with head and neck squamous cell carcinoma who were being treated to evaluate whether circulating tumor cells that overexpress PD-L1 can be detected at baseline (before treatment) and at different treatment time points to predict treatment After the clinical effect.
Masu binciken sun haɓaka ƙayyadaddun kayan aikin RT-qPCR don gano maganganun PD-L1 mRNA a cikin ƙwayoyin CTC masu inganci na EpCAM. Binciken ya yi rajistar marasa lafiya 113 tare da ci gaba da kai da wuyan squamous cell carcinoma kuma an gano maganganun PD-L1 a cikin sel CTC masu kyau na EpCAM a tushen asali, bayan hawan keke na 2 na induction chemotherapy (makonni 6), kuma bayan matakin chemoradiation (makonni 15) na lokaci guda.
Sakamakon ya nuna cewa a asali, 25.5% (24/94) marasa lafiya suna da PD-L1 overexpression a cikin CTCs. Adadin wuce gona da iri bayan shigar da chemotherapy shine 23.5% (8/34), da 22.2% (12/54). Bayan jiyya, marasa lafiya tare da CTC har yanzu suna overexpressing PD-L1 suna da ɗan gajeren rayuwa ba tare da ci gaba ba (P=0.001) da gajeriyar rayuwa gabaɗaya (P <0.001).
Bayan jiyya, PD-L1 ba tare da wuce gona da iri ba na iya zama mafi kusantar cimma cikakkiyar gafara (OR = 16, 95% CI 2.76 ~ 92.72; P=0.002).
